Pioneers precision immunology by developing patient-specific therapies that prioritize individual biological responses over traditional molecule-first approaches. This method addresses the limitations of generic treatments for immune-mediated diseases, aiming to deliver more effective and personalized therapeutic options.
Funding
$64M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCGCMFFounders
Product
Problem
Current treatments for immune-mediated diseases often take a molecule-first approach, which can lead to ineffective or inadequate responses due to the complex and individual nature of human biology. This one-size-fits-all approach fails to account for the unique biological characteristics of each patient, resulting in suboptimal therapeutic outcomes.
Solution
Endpoint Health is developing precision-first therapeutics by prioritizing individual patient biological responses over traditional molecule-first drug development. The company leverages a proprietary artificial intelligence (AI) platform to combine companion diagnostics with targeted therapeutics, creating personalized treatment strategies. By focusing on precision immunology, Endpoint Health aims to address unmet needs in both chronic and acute immune-mediated diseases. This approach involves building a clinical and data ecosystem to deliver tailored therapies that are more effective and aligned with each patient's unique biological and disease profile.
Target Audience
The primary target audience includes patients with immune-mediated chronic and acute diseases, as well as healthcare providers seeking more effective and personalized treatment options.
Features
- Proprietary AI platform for analyzing patient-specific biological responses
- Development of companion diagnostics to identify ideal candidates for targeted therapies
- Precision-first approach that prioritizes patient biology over molecule-first drug development
- Focus on immune-mediated chronic and acute diseases